Literature DB >> 7010382

Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone.

A Nissinen, J Tuomilehto.   

Abstract

A double-blind, within-patient study was carried out in 23 newly diagnosed patients with mild to moderate hypertension (diastolic blood pressure of at least 100 mmHg) to compare the antihypertensive effects of atenolol (100 mg) and chlorthalidone (25 mg) given in free and fixed combination. After a 4-week placebo run-in period, patients received each of the two active treatments and also placebo for periods of 4 weeks, the treatment sequence being randomized. A single daily drug dose was taken 24 to 28 hours before each blood pressure measurement at 2-weekly intervals. The results showed that both active drug combinations lowered lying, standing and post-exercise blood pressure significantly and there was no statistical difference between the two forms of treatment. Two-thirds of the patients were adequately controlled with the single daily dose regimen and few side-effects were reported.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7010382

Source DB:  PubMed          Journal:  Pharmatherapeutica        ISSN: 0308-051X


  3 in total

Review 1.  Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis.

Authors:  Paweł Kawalec; Przemysław Holko; Małgorzata Gawin; Andrzej Pilc
Journal:  Arch Med Sci       Date:  2018-08-13       Impact factor: 3.318

2.  Safety of Fixed Dose of Antihypertensive Drug Combinations Compared to (Single Pill) Free-Combinations: A Nested Matched Case-Control Analysis.

Authors:  Emmanuel Nowak; André Happe; Jacques Bouget; Francois Paillard; Cécile Vigneau; Pierre-Yves Scarabin; Emmanuel Oger
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

Review 3.  Free versus Fixed Combination Antihypertensive Therapy for Essential Arterial Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Samir G Mallat; Bassem Y Tanios; Houssam S Itani; Tamara Lotfi; Elie A Akl
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.